Literature DB >> 27566221

Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study.

Simone Ferrero1, Franco Alessandri2, Valerio Gaetano Vellone3, Pier Luigi Venturini4, Umberto Leone Roberti Maggiore4.   

Abstract

OBJECTIVE: To assess the usefulness of 3-month treatment with ulipristal acetate (UPA) before laparoscopic myomectomy of large uterine myomas. STUDY
DESIGN: This retrospective analysis of a prospectively collected database included women of reproductive age requiring laparoscopic myomectomy with the following characteristics: FIGO type 3, 4 or 5 myomas; largest diameter of the main myoma ≥10cm; number of myomas ≤3; largest diameters of the other myomas ≤5cm (second myoma) and ≤3cm (third myoma). Patients either underwent direct surgery (group S) or were treated before surgery with UPA for 3 months (group UPA).
RESULTS: The mean (±SD) intraoperative blood loss was lower in group UPA (507.1±214.9ml) than in group S (684.2±316.8; p=0.012). The total operative time was lower in group UPA (137.6±26.8min) than in group S (159.7±26.8min; p<0.001); there was no significant difference in the suturing time between the two study groups (p=0.076). Hemoglobin drop was lower in group UPA (1.1±0.5g/dl) than in group S (1.3±0.7g/dl; p=0.034). Six patients in group S and no patient in group UPA required postoperative blood transfusions (p=0.031). Complications were not different between the two groups (p=0.726). Moreover, preoperative treatment with UPA caused a significant increase in hemoglobin levels (11.9±1.6g/dl) compared with baseline (9.1±1.1g/dl; p<0.001).
CONCLUSION: A 3-month treatment with UPA before laparoscopy for large uterine myomas decreases intraoperative blood loss, hemoglobin drop, postoperative blood transfusion and length of surgery.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Myomectomy; Surgery; Ulipristal acetate; Uterine myoma

Mesh:

Substances:

Year:  2016        PMID: 27566221     DOI: 10.1016/j.ejogrb.2016.08.021

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  8 in total

1.  What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of "real-world" data.

Authors:  Neha Shah; Elizabeth Egbase; Michael Sideris; Funlayo Odejinmi
Journal:  Arch Gynecol Obstet       Date:  2021-01-02       Impact factor: 2.344

2.  Current Practices for Treatment of Uterine Fibroids.

Authors:  Shalini Singh; Tanmay Thulkar; Monisha Pawanarkar; Jyoti Thulkar
Journal:  J Midlife Health       Date:  2017 Oct-Dec

Review 3.  Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis.

Authors:  Inge de Milliano; Moniek Twisk; Johannes C Ket; Judith A Huirne; Wouter J Hehenkamp
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

Review 4.  Ulipristal acetate before high complexity endoscopic (hysteroscopic, laparoscopic) myomectomy - a mini-review.

Authors:  Włodzimierz Baranowski
Journal:  Prz Menopauzalny       Date:  2017-02-08

5.  The Use of Ulipristal Acetate (Esmya) Prior to Laparoscopic Myomectomy: Help or Hindrance?

Authors:  Rebecca Mallick; Sam Oxley; Funlayo Odejinmi
Journal:  Gynecol Minim Invasive Ther       Date:  2019-04-29

6.  Esmolol Infusion Reduces Blood Loss and Opiate Consumption during Fertility Preserving Myomectomy.

Authors:  Jehan Mohammad Ezzat Hamed; Walid Mamdouh Ataalla
Journal:  Anesth Essays Res       Date:  2019 Jul-Sep

Review 7.  The Significant Risk Factors of Intra-Operative Hemorrhage during Laparoscopic Myomectomy: A Systematic Review.

Authors:  Zaki Sleiman; Rania El Baba; Simone Garzon; Aline Khazaka
Journal:  Gynecol Minim Invasive Ther       Date:  2019-11-11

Review 8.  Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Authors:  Funlayo Odejinmi; Reeba Oliver; Rebecca Mallick
Journal:  Womens Health (Lond)       Date:  2017-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.